Skip to main content
SpringerLink
Log in

Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer

  • Chapter
General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Part of the book series: Methods of Cancer Diagnosis, Therapy, and Prognosis ((HAYAT,volume 2))

  • 1110 Accesses

Prostate Cancer is the most common non-skin cancer affecting men in the United States. The National Cancer Institute estimates that ̃218,890 new cases and 27,050 deaths will be attributed to this disease in 2007. During the course of the disease, roughly 30–50% of patients will have metastatic progression (Gittes, 1991). In the mid 1980s, androgen deprivation by bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists showed tumor stabilization or regression in 80–95% of patients (Parmar et al., 1985). These therapies ultimately fail and these patients progress to a hormone refractory disease state in a median of 18–36 months (Aragon-Ching and Dahut, 2007).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aragon-Ching, J.B., and Dahut, W.L. 2007. Chemotherapy in androgen-independent prostate cancer (AIPC): What's next after taxane progression? Cancer Ther. 5A: 151–160

    PubMed  Google Scholar 

  • Borden, L.S. Jr., Clark, P.E., Lovato, J., Hall, M.C., Stindt, D., Harmon, M., Mohler, R., and Torti, F.M. 2006. Vinorelbine, doxorubicin, and pred-nisone in androgen-independent prostate cancer. Cancer 107: 1093–1100

    Article  PubMed  CAS  Google Scholar 

  • DeWys, W.D., Bauer, M., Colsky, J., Cooper, R.A., Creech, R., and Carbone P.P. 1977. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer — progress report. Cancer Treat. Rep. 61: 325–328

    Google Scholar 

  • Fields-Jones, S., Koletsky, A., Wilding, G., O'Rourke, M., O'Rourke, T., Eckardt J., Yates, B., McGuirt, C., and Burris, H.A. 3rd. 1999. Improvements in clinical benefit with vinor-elbine in the treatment of hormone-refractory prostate cancer: a Phase II trial. Ann. Oncol. 10: 1307–1310

    Article  PubMed  CAS  Google Scholar 

  • Fosså, S.D., Slee, P.H., Brausi, M., Horenblas, S., Hall, R.R., Hetherington, J.W., Aaronson, N., de Prijck, L., and Collette, L. 2001. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after andro-gen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J. Clin. Oncol. 19: 62–71

    PubMed  Google Scholar 

  • Gittes, R.F. 1991. Carcinoma of the prostate. N. Engl. J. Med. 324: 236–245

    PubMed  CAS  Google Scholar 

  • Gregurich, M. 2000. Phase III study of mitoxantrone/ low-dose prednisone versus low-dose prednisone alone in patients with asymptomatic hormone-refractory carcinoma of the prostate. Proc. Am. Soc. Clin. Oncol. 18: 1440–1450. Abstract

    Google Scholar 

  • Haas, N.B., Manola, J., Hudes, G., Citrin, D.L., Kies, M.S., and Davis, T.E., Eastern Cooperative Oncology Group Study PH882. 2000. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am. J. Clin. Oncol. 23: 589–592

    Article  PubMed  CAS  Google Scholar 

  • Lacy, C.F., Armstrong. L.L., and Goldman, M.P. 2003. Narcotic Agonists Comparative Pharmacokinetics. Drug Information Handbook, 11th ed. Hudson, OH: Lexi-Comp

    Google Scholar 

  • Mike, S., Harrison, C., Coles, B., Staffurth J., Wilt, T.J., and Mason, M.D. 2006. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst. Rev. 18(4): CD005247

    Google Scholar 

  • Miller, G.M., and Hinman, F. Jr. 1954. Cortisone treatment in advanced carcinoma of the prostate. J. Urol. 72: 485–496

    PubMed  CAS  Google Scholar 

  • Morant, R., Hsu Schmitz, S.F., Bernhard, J., Thürlimann, B., Borner, M., Wernli, M., Egli, F., Forrer, P., Streit, A., Jacky, E., Hanselmann, S., Bauer, J., Hering, F., Schmid, H.P. 2002. Vinorelbine in androgen-independent metastatic prostatic carcinoma — a Phase II study. Eur. J. Cancer 38: 1626–1632

    Article  PubMed  CAS  Google Scholar 

  • O'Bryan, R.M., Baker, L.H., Gottlieb, J.E., Rivkin, S.E., Balcerzak, S.P., Grumet, G.N., Salmon,S.E., Moon, T.E., and Hoogstraten, B. 1977. Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940–1948

    Article  PubMed  Google Scholar 

  • Osoba, D., Tannock, I.F., Ernst, D.S., Neville, A.J. 1999. Health-related quality of life in men with metastatic prostate cancer treated with pred-nisone alone or mitoxantrone and prednisone. J. Clin. Oncol. 17: 1654–1663

    PubMed  CAS  Google Scholar 

  • Oudard, S., Caty, A., Humblet, Y., Beauduin, M., Suc, E., Piccart, M., Rolland, F., Fumoleau, P., Bugat, R., Houyau, P., Monnier, A., Sun, X., Montcuquet, P., Breza, J., Novak, J., Gil, T., and Chopin, D. 2001. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann. Oncol. 12: 847–852

    Article  PubMed  CAS  Google Scholar 

  • Parmar, H., Phillips, R.H., Lightman, S.L., Edwards, L., Allen, L., and Schally, A.V. 1985. Randomized controlled study of orchiectomy versus long-acting D-trp-6-LHRH microcap-sules in advanced prostate carcinoma. Lancet 2: 1201–1205

    Article  PubMed  CAS  Google Scholar 

  • Raghavan, D. 1988. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol. 15: 371–389

    PubMed  CAS  Google Scholar 

  • Rangel, C., Matzkin, H., and Soloway, M.S. 1992. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory Stage D2 prostate cancer. Urology. 39: 577–582

    Article  PubMed  CAS  Google Scholar 

  • Robles, C., Furst, A.J., Sriratana, P., Lai, S., Chua, L., Donnelly, E., Solomon, J., Sundaram, M., Feun, L., and Savaraj, N. 2003. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncol. Rep. 10: 885–889

    PubMed  CAS  Google Scholar 

  • Small, E.J., Srinivas, S., Egan, B., McMillan, A., and Rearden, T. P. 1996. Doxorubicin and dose-escalated cyclophosphamide with granulo-cyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J. Clin. Oncol. 14: 1617–1625

    PubMed  CAS  Google Scholar 

  • Smith, M.R., Kaufman, D., Oh, W., Guerin, K., Seiden, M., Makatsoris, T., Manola, J., and Kantoff, P.W. 2000. Vinorelbine and estra-mustine in androgen-independent metastatic prostate cancer: a Phase II study. Cancer 89: 1824–1828

    Article  PubMed  CAS  Google Scholar 

  • Sweeney, C.J., Monaco, F.J., Jung, S.H., Wasielewski, M.J., Picus, J., Ansari, R.H., Dugan, W.M., and Einhorn, L.H. 2002. A Phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann. Oncol. 13: 435–440

    Article  PubMed  CAS  Google Scholar 

  • Tannock, I., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., and Rider, W. 1989. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7: 590–597

    PubMed  CAS  Google Scholar 

  • Tannock, I.F., Osoba, D., Stockler, M.R., Ernst, D.S., Neville, A.J., Moore, M.J., Armitage, G.R., Wilson, J.J., Venner, P.M., Coppin, C.M., and Murphy, K.C. 1996. Chemotherapy with mitox-antrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14: 1756–1764

    PubMed  CAS  Google Scholar 

  • Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., Oudard, S., Théodore, C., James, N.D., Turesson, I., Rosenthal, M. A., and Eisenberger, M.A.; TAX 327 Investigators. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15): 1502–1512

    Article  PubMed  CAS  Google Scholar 

  • Torti, F.M., Aston, D., Lum, B.L., Kohler, M., Williams, R., Spaulding, J.T., Shortliffe, L., and Freiha, F.S. 1983a. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J. Clin. Oncol. 1: 477–482

    CAS  Google Scholar 

  • Torti, F.M., Bristow, M.R., Howes, A.E., Aston, D., Stockdale, F.E., Carter, S.K., Kohler, M., Brown, B.W. Jr., and Billingham, M. E. 1983b. Reduced cardiotoxiCity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann. Intern. Med. 99: 745–749

    CAS  Google Scholar 

  • Tralongo, P., Bollina, R., Aiello, R., Di Mari, A., Moruzzi, G., Beretta, G., Mauceri, G., and Conti, G. 2003. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A Phase II study. Tumori 89: 26–30

    PubMed  CAS  Google Scholar 

  • Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L. Jr., Von Hoff, A.L., Rozencweig, M., and Muggia, F.M. 1979. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91: 710–717

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center, Wake Forest University, School of Medicine, Winston Salem, NC, 27157

    Samer Kalakish & Frank M. Torti

Authors
  1. Samer Kalakish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank M. Torti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samer Kalakish .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Kean University, Union, NJ, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media B.V

About this chapter

Cite this chapter

Kalakish, S., Torti, F.M. (2008). Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer. In: Hayat, M.A. (eds) General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Methods of Cancer Diagnosis, Therapy, and Prognosis, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8442-3_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-8442-3_38

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-8441-6

  • Online ISBN: 978-1-4020-8442-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation